Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | TOP1 | P11387 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.53 |
| ▸ | PPARD | Q03181 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | F7 | P08709 | 5/20 | 0.53 |
| ▸ | F3 | P13726 | 5/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | TERT | O14746 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | FABP4 | P15090 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704911 | 0.98 | MAPT (0.58) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL3704145 | 0.98 | MAPT (0.58) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL3702710 | 0.97 | MAPT (0.57) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL3707984 | 0.97 | MAPT (0.57) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL3704192 | 0.97 | MAPT (0.57) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL18212571 | 0.97 | MAPT (0.57) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL7031615 | 0.97 | MAPT (0.57) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL4443016 | 0.91 | TOP1 (0.70) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL29497770 | 0.91 | TOP1 (0.70) | MAPTTOP1PPARGPPARDPPARA | |
| SCHEMBL3702247 | 0.88 | MAPT (0.74) | MAPTTOP1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10287262-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-14 | — | — | US | disclosed |
| EP-3222612-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2010081683-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2010-07-22 | — | — | WO | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | MAPT 4873/4885TOP1 3264/4885PPARG 72/4885 |
| US-10287262-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | MAPT 4861/4885TOP1 3159/4885PPARG 58/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | MAPT 4861/4885TOP1 3159/4885PPARG 58/4885 |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | MAPT 4864/4885TOP1 3120/4885PPARG 72/4885 |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | MAPT 4864/4885TOP1 3120/4885PPARG 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.